ASX pot-stock RotoGro scores $2.3M order

Published at Apr 4, 2018, in Biotech

RotoGro World Wide (Canada) Inc., a wholly-owned subsidiary of RotoGro International Limited (ASX:RGI), has secured a $2.3 million order from Miracle Valley Medical Alternatives M.V.M.A. Ltd., a Health Canada licensed producer.

RGI is an Australian-based company with licensed, proprietary, patented and patents-pending technology in the stackable rotary hydroponic garden space. It also holds worldwide exclusive licenses for legalised medicinal and recreational cannabis markets, as well licences as for all other purposes including pharmaceuticals, health and nutrition supplements, nutraceuticals and perishable foods.

Miracle Valley is currently building a 29,000 square foot state-of-the-art cultivation and manufacturing facility in British Columbia, Canada.

Phase one of the facility comprises some 10,000 square feet of grow rooms outfitted with RotoGro Hydroponic Garden Systems, to be stacked two units high and in four-unit pods, complete with the RotoGro propriety iGrow™ software grow management system.

Miracle Valley projects that the facility will produce up to 12,000 lbs (5,400 kilograms) of legal cannabis per year, harnessing RGI’s leading-edge patented and patent-pending designs, which provide the lowest cost per gram and the highest yield per square foot in the industry.

This order is the culmination of several months of collaboration, whereby RGI provided Miracle Valley with front-end technical support and facility design solutions across the spectrum of building selection, electrical and mechanical design, liaison with local municipalities, installation specifications, and building layout and optimisation.

As part of the order, RGI will provide onsite assembly, installation, testing, certification, training and growing management support.

It’s worth noting here that this is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.

RGI managing director, Michael Carli, said: “The successful award of the Miracle Valley order is a major milestone in RotoGro’s quest to becoming the world leader in hydroponic agricultural technology.”

“The order provides the company with its first large-scale Health Canada Licensed Producer, which will be a flagship to promote further large-scale orders of our RotoGro Hydroponic Garden Systems.”

“Currently, there are 93 Health Canada Licensed Producers in Canada with a further 208 applicants in the final stage of the Health Canada licensing process,” Carli noted. “Our RotoGro team has been working diligently with numerous prospective clients, and the award of the Miracle Valley order is a testament to their ongoing efforts from initial enquiry to securing the order.”

“We will continue targeting and working with lawful cannabis cultivators and perishables growers to nurture our sales pipeline for future orders. Each inquiry brings unique technical support and design needs which require our team to remain solution and outcome oriented in order to provide the most suitable solution for our customers,” Carli added.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn